EHMTI-0178. CGRP monoclonal antibody LY2951742 for the prevention of migraine: a phase 2, randomized, double-blind, placebo-controlled study

Detalles Bibliográficos
Autores principales: Goadsby, P, Dodick, D, Spierings, E, Scherer, J, Sweeney, S, Grayzel, D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer 2014
Materias:
Meeting Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4182069/
http://dx.doi.org/10.1186/1129-2377-15-S1-G10
_version_ 1782337475922886656
author Goadsby, P
Dodick, D
Spierings, E
Scherer, J
Sweeney, S
Grayzel, D
author_facet Goadsby, P
Dodick, D
Spierings, E
Scherer, J
Sweeney, S
Grayzel, D
author_sort Goadsby, P
collection PubMed
description
format Online
Article
Text
id pubmed-4182069
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Springer
record_format MEDLINE/PubMed
spelling pubmed-41820692014-10-02 EHMTI-0178. CGRP monoclonal antibody LY2951742 for the prevention of migraine: a phase 2, randomized, double-blind, placebo-controlled study Goadsby, P Dodick, D Spierings, E Scherer, J Sweeney, S Grayzel, D J Headache Pain Meeting Abstract Springer 2014 2014-09-18 /pmc/articles/PMC4182069/ http://dx.doi.org/10.1186/1129-2377-15-S1-G10 Text en Copyright © 2014 Goadsby et al; licensee Springer. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Meeting Abstract
Goadsby, P
Dodick, D
Spierings, E
Scherer, J
Sweeney, S
Grayzel, D
EHMTI-0178. CGRP monoclonal antibody LY2951742 for the prevention of migraine: a phase 2, randomized, double-blind, placebo-controlled study
title EHMTI-0178. CGRP monoclonal antibody LY2951742 for the prevention of migraine: a phase 2, randomized, double-blind, placebo-controlled study
title_full EHMTI-0178. CGRP monoclonal antibody LY2951742 for the prevention of migraine: a phase 2, randomized, double-blind, placebo-controlled study
title_fullStr EHMTI-0178. CGRP monoclonal antibody LY2951742 for the prevention of migraine: a phase 2, randomized, double-blind, placebo-controlled study
title_full_unstemmed EHMTI-0178. CGRP monoclonal antibody LY2951742 for the prevention of migraine: a phase 2, randomized, double-blind, placebo-controlled study
title_short EHMTI-0178. CGRP monoclonal antibody LY2951742 for the prevention of migraine: a phase 2, randomized, double-blind, placebo-controlled study
title_sort ehmti-0178. cgrp monoclonal antibody ly2951742 for the prevention of migraine: a phase 2, randomized, double-blind, placebo-controlled study
topic Meeting Abstract
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4182069/
http://dx.doi.org/10.1186/1129-2377-15-S1-G10
work_keys_str_mv AT goadsbyp ehmti0178cgrpmonoclonalantibodyly2951742forthepreventionofmigraineaphase2randomizeddoubleblindplacebocontrolledstudy
AT dodickd ehmti0178cgrpmonoclonalantibodyly2951742forthepreventionofmigraineaphase2randomizeddoubleblindplacebocontrolledstudy
AT spieringse ehmti0178cgrpmonoclonalantibodyly2951742forthepreventionofmigraineaphase2randomizeddoubleblindplacebocontrolledstudy
AT schererj ehmti0178cgrpmonoclonalantibodyly2951742forthepreventionofmigraineaphase2randomizeddoubleblindplacebocontrolledstudy
AT sweeneys ehmti0178cgrpmonoclonalantibodyly2951742forthepreventionofmigraineaphase2randomizeddoubleblindplacebocontrolledstudy
AT grayzeld ehmti0178cgrpmonoclonalantibodyly2951742forthepreventionofmigraineaphase2randomizeddoubleblindplacebocontrolledstudy

Ejemplares similares